论文部分内容阅读
目的研究培美曲塞(Alimta)联合长春瑞滨(NVB)治疗老年中晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法入组33例老年中晚期非小细胞肺癌初治或复治患者,培美曲塞500mg/m2,静脉滴注10min以上,第1天;长春瑞滨25mg/m2,加生理盐水40ml静脉推注,第1、8天,每3周为一周期,2个周期后评价疗效。结果 33例患者中完全缓解(CR)1例,部分缓解(PR)17例,稳定(SD)9例,进展(PD)6例,有效率(CR+PR)54.5%。结论培美曲塞(Pemetrexed Alim-ta)联合长春瑞滨(Navelbine,NVB)治疗老年中晚期非小细胞肺癌(NSCLC)的疗效较好,副作用可耐受,可作为治疗老年中晚期非小细胞肺癌(NSCLC)的一线或二线化疗方案。
Objective To investigate the efficacy and adverse reactions of Alimta combined with vinorelbine (NVB) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 33 elderly patients with advanced or reconstructive non-small cell lung cancer were enrolled in this study. Pemetrexed 500mg / m2, intravenous drip 10min or more, on day 1, vinorelbine 25mg / m2, saline 40ml intravenously Note, on the first day, every 3 weeks for a cycle, 2 cycles after the evaluation of efficacy. Results Among 33 patients, there were 1 complete remission (CR), 17 partial remission (PR), 9 stable (SD) and 6 progressive (PD) patients. The response rate was 54.5%. Conclusion Pemetrexed Alim-ta and NVB are effective in treating middle-late stage non-small cell lung cancer (NSCLC). The side effects are tolerable and can be used as a treatment for advanced non-small cell First-line or second-line chemotherapy for lung cancer (NSCLC).